Summary of Cullinan Therapeutics Conference Call Company Overview - **Company**: Cullinan Therapeutics (NasdaqGS: CGEM) - **Year**: 2026 is highlighted as a potentially defining year for the company with multiple milestones across programs, particularly focusing on T-cell engager programs CLN-978 and CLN-049 [17][21] Key Programs and Developments CLN-978 (CD19xCD3 T-cell engager) - **Indications**: Targeting autoimmune diseases such as lupus, rheumatoid arthritis (RA), and Sjögren's disease - **Differentiation**: Claimed to be a potential best-in-class molecule with high affinity binding for CD19 and small molecular size for better tissue penetration [17][18] - **Clinical Data Timeline**: - Q2 2026: Initial clinical data from systemic lupus erythematosus (SLE) and RA - Q3 2026: Initial multi-dose data from RA - Q4 2026: Initial data from Sjögren's disease study [18] - **Market Interest**: The B-cell depletion space remains attractive, as evidenced by recent acquisitions in the sector [18] CLN-049 (FLT3xCD3 T-cell engager) - **Indication**: Focused on acute myeloid leukemia (AML) - **Efficacy Data**: Presented compelling monotherapy efficacy data at ASH, with Fast Track designation from the FDA received [19] - **Clinical Development**: - Plans to initiate a phase 1/2 study in combination with venetoclax in the frontline setting by the end of 2026 [19][94] - Aiming for a pivotal study in relapsed refractory disease [19] Zipalertinib - **Milestone**: Completed NDA submission, marking a significant achievement for the company [20] Financial Position - **Cash Reserves**: Over $430 million reported at the end of the previous year, providing a runway into 2029 to advance programs [21] Competitive Landscape - **Positioning**: CLN-978 is positioned against other CD19 T-cell engagers, with a focus on its high binding affinity and small size for better tissue penetration [42][43] - **Competitors**: Companies like Roche, Novartis, Merck, and GSK are mentioned as competitors, with some being further behind in development [42][43] Clinical Insights and Data - **B-cell Depletion**: Emphasized the importance of deep B-cell depletion for achieving treatment-free remission in autoimmune diseases [26][27] - **Durability of Response**: Noted that some patients have achieved treatment-free responses lasting several years, particularly in diseases like systemic lupus erythematosus [33] - **Safety Profile**: Initial studies showed favorable safety profiles with low rates of cytokine release syndrome (CRS) [67][92] Future Outlook - **Upcoming Data**: Anticipated updates at ASH or EHA, with a focus on further dose escalation and durability of response [95][96] - **Regulatory Pathway**: Clear development pathway for AML with potential for approval in relapsed refractory disease through a single-arm study [94] Conclusion - **Strategic Focus**: Cullinan Therapeutics is poised for a significant year in 2026 with multiple clinical milestones, a strong financial position, and a competitive edge in the T-cell engager space, particularly in autoimmune diseases and AML [21][94]

Ardelyx (NasdaqGM:ARDX) 2026 Conference March 10, 2026 04:20 PM ET Company ParticipantsEric Foster - Chief Commercial OfficerLaura Williams - Chief Patient OfficerMike Raab - President and CEOSue Hohenleitner - CFOConference Call ParticipantsRoanna Ruiz - Senior Biotechnology AnalystRoanna RuizGlobal Healthcare Conference. My name is Roanna Ruiz. I'm one of the Senior Biotech Analysts here, and it is my pleasure to introduce the Ardelyx team with me. I've got the full lineup here. We've got Mike Raab, CEO, ...

Summary of 4D Molecular Therapeutics Conference Call Company Overview - **Company**: 4D Molecular Therapeutics (NasdaqGS:FDMT) - **Event**: 2026 Leerink Partners Global Healthcare Conference - **Date**: March 10, 2026 Key Points Enrollment and Clinical Trials - **4FRONT Program**: Focus on the speed and completion of enrollment for the 4FRONT program, which includes two Phase 3 studies: 4FRONT-1 (U.S.) and 4FRONT-2 (global) [3][4] - **Enrollment Success**: 4FRONT-1 completed enrollment in 11 months, ahead of the projected 18 months, with approximately 500 patients enrolled [5] - **Patient Need**: High unmet need and physician enthusiasm reflected in the rapid enrollment [5][6] - **ASRS PAT Survey**: 54% of retina specialists find gene therapy the most exciting development, indicating strong interest in 4D-150 [7] Product Details - **Lead Asset**: 4D-150, targeting wet AMD and DME, designed to express aflibercept with low inflammatory potential [4] - **Efficacy**: In the PRISM study, 80% reduction in treatment burden for severe patients; 90% reduction for recently diagnosed patients, with 70% injection-free [10][11] - **Patient Population**: Focus on treatment-naive patients for pivotal trials, which aligns with FDA expectations for vision benefit [13][14] Market Dynamics - **U.S. vs. EU**: Different reimbursement models; U.S. relies on a buy-and-bill model while EU pricing is more government-controlled [19][20] - **Economic Benefits**: 4D-150 expected to alleviate treatment burden and improve practice capacity, making it economically beneficial for clinics [19] - **Vision Preservation**: Potential to show long-term vision preservation, which is a significant value proposition for payers [21][38] Commercialization Strategy - **Physician Engagement**: Ongoing efforts to educate physicians on the new treatment model, shifting from "treat and extend" to "treat and monitor" [24][26] - **Medical Team Development**: Plans to build a medical team to engage with the retina community ahead of product approval [29] - **International Markets**: Partnering for commercialization in Asia Pacific, with Japan as a key market; potential for similar partnerships in Europe post-Phase 3 data [31][32] Financial Overview - **Cash Position**: As of December 31, over $510 million in cash, with a runway extending into the second half of 2028 [58] - **Funding for Trials**: DME trial fully funded; commercial ramp-up post-4FRONT-1 data not yet funded [58] Future Opportunities - **DME and Diabetic Retinopathy**: Significant under-treatment in DME presents a large market opportunity; potential to expand into diabetic retinopathy [48][50] - **Regulatory Alignment**: Alignment with FDA and EMA for DME study filing, indicating a streamlined path for future studies [48] Additional Considerations - **Pricing Strategy**: Need to balance pricing between U.S. and EU markets, considering the impact of MFN (Most Favored Nation) policies [36][39] - **Long-term Vision**: Emphasis on the importance of demonstrating the value of 4D-150 in preserving vision and reducing treatment burden to justify pricing [37][38] This summary encapsulates the critical insights from the conference call, highlighting the company's strategic direction, product potential, and market dynamics.

Axsome Therapeutics Conference Call Summary Company Overview - **Company**: Axsome Therapeutics (NasdaqGM:AXSM) - **Industry**: Biopharmaceuticals, focusing on central nervous system (CNS) disorders - **Mission**: Develop transformative medicines for CNS conditions affecting hundreds of millions globally [6][7] Key Financial Highlights - **2025 Performance**: - Auvelity generated over **$500 million** in revenue, marking its third year since launch - Total sales for the company approached **$640 million** [7][8] - **2026 Expectations**: - Anticipation of a PDUFA date for Auvelity in Alzheimer's disease agitation on **April 30, 2026** [7][8] - **Team Expansion**: Plans to increase the workforce from **300 to 600** employees [8] Product Portfolio - **Current Products**: - Three on-market products: Auvelity, Sunosi, and SYMBRAVO - Peak sales potential for these products estimated between **$2 billion to $5 billion** [10][18] - **Pipeline**: - Five differentiated product candidates with **seven late-stage clinical trials** [10][11] - Total peak sales potential for pipeline conditions exceeds **$16 billion**, affecting over **150 million patients** [11][12] Product-Specific Insights - **Auvelity**: - Approved for major depressive disorder; expected peak sales for Alzheimer's agitation between **$1.5 billion to $3 billion** [14][34] - Currently holds **86%** market access coverage, with plans to enhance primary care market penetration [22][23] - **Sunosi**: - Revenue growth of **40% year-over-year**; currently generating **$300 million to $500 million** [27][28] - **SYMBRAVO**: - Launched in June 2025; initial growth observed with plans to improve payer coverage [19][30] Clinical Trials and Future Developments - **AXS-05**: - Undergoing review for Alzheimer's disease agitation; three positive trials supporting the application [34][36] - **AXS-12**: - NDA submission for cataplexy in narcolepsy imminent [41] - **Solriamfetol**: - Involved in multiple phase 3 trials for ADHD, major depressive disorder with excessive daytime sleepiness, binge eating disorder, and shift work disorder [37][39][40] Financial Position - **Cash Position**: - **$323 million** on the balance sheet, with a small debt of around **$190 million** [45] - **Revenue Growth**: - Revenues grew three times faster than operating expenses in 2025, with expectations for continued operating leverage in 2026 [45][46] Strategic Focus for 2026 - **Growth Initiatives**: - Focus on commercial performance, R&D advancement, and team expansion to support business growth [17][18] - **Market Access**: - Continued efforts to improve formulary access and expand into primary care markets [22][23] Conclusion - Axsome Therapeutics is well-positioned for growth in 2026, with a strong product pipeline, significant revenue potential, and strategic initiatives aimed at expanding market access and enhancing operational efficiency [45][46]

The following slides contain summaries of certain financial and statistical information about SuRo Capital. The information contained in this presentation is summary information intended to be considered in connection with review of our SEC filings and other public announcements we may make, by press release or otherwise, from time to time. We undertake no duty or obligation to publicly update or revise the information contained in this presentation unless required to do so by law. In addition, information ...

NASDAQ: BBCP INVESTOR PRESENTATION | March 2026 Disclaimer Forward-Looking Statements This investor presentation includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. The Company's actual results may differ from expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "for ...

4Q 2025 INVESTOR PRESENTATION March 10, 2026 We make the American Dream of home possible. Partnering with homeowners throughout the lifecycle of the homeownership journey. Serving the Buyer First Time Homebuyer Veteran / Active Duty Move Up / Downsize Relocation Supporting the Purchase Servicing the Mortgage Optimizing the Journey Title Services Escrow/ Closing Homeowners Insurance Building Trust Continuing Customer Relationship Facilitate additional lending opportunities HELOC Closed-End Second Refinance S ...

Q4 and Full Year 2025 Results March 10, 2026 This presentation provides select highlights about Motorsport Games Inc.'s results of operations. Please see Motorsport Games' 2025 Form 10-K, filed with the SEC and Q4 and full year 2025 earnings release for more complete information on the Company's results of operations, cash flows, financial condition and liquidity. motorsportgames 1 Q4 2025 Highlights Financial Highlights Key Highlights – FY 2025 and Subsequent Update *Adjusted EBITDA is a non-GAAP financial ...

FY 2025 Investor Supplement LAST UPDATED 03.10.2026 © 2026 Finance of America Companies Disclaimer Forward Looking Statements This presentation includes forward-looking statements within the meaning of the "safe harbor" provisions of the United States of America (the "U.S.") Private Securities Litigation Reform Act of 1995. Forward-looking statements are not historical facts or statements of current conditions, but instead represent only the Company's beliefs regarding future events, many of which, by their ...

CONNECT WITH NATURE Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking statements regarding the Company's future business expectations, which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may include, but are not limited to, statements relating to our objectives, plans, strategies and financial results, including expected improvement in gross profit and gross margin. All statements (o ...